CheckMate 275: efficac
a
By RECIST v1.1
b
265 of 270 patients were evaluated for efficacy, as 5 patients had insufficient follow-up
c
Similar results were seen using the 5% PD-L1 tumour expression cut-off; NR, not reached
Sharma P et al. Lancet 2017; Galsky et al. ESMO 2016
Outcome, %
All
N=265
b
PD-L1 <1%
n=143
PD-L1 ≥1%
n=122
PD-L1 ≥5%
n=81
Confirmed ORR by
BIRC
a
19.6
16.1
23.8
28.4
95% CI
15.0–24.9 10.5–23.1 16.5–32.3 18.9–39.5
Best overall response
CR
2.3
<1
4.1
4.9
PR
17.4
15.4
19.7
23.5
SD
22.6
17.5
28.7
28.4
PD
39.2
46.9
30.3
25.9
Unable to
determine
18.5
19.6
17.2
17.3
Median OS,
months (95% CI)
c
All treated
PD-L1 <1%
PD-L1 ≥1%
8.74 (6.05–NR)
5.95 (4.30–8.08)
11.30 (8.74–NR)
0
0.2
0.4
0.6
0.8
1.0
0
3
6
9
12
15
Overall survival (probability)
Months
